Status:
TERMINATED
Impact of Cannabis on Pain and Inflammation Among Patients With Rheumatoid or Psoriatic Arthritis
Lead Sponsor:
Brown University
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Rheumatoid Arthritis
Psoriatic Arthritis
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This laboratory study will investigate the impact of cannabis on pain, affect, and inflammation among patients with rheumatoid or psoriatic arthritis (n = 76). Two cannabis formulations varying in pot...
Detailed Description
This laboratory study will investigate the impact of cannabis on pain, affect, and inflammation among patients with rheumatoid or psoriatic arthritis (n = 76). Two cannabis formulations varying in pot...
Eligibility Criteria
Inclusion
- current RA or PA diagnosis with active arthritis not adequately controlled by standard medication
- if taking prescribed steroid, non-steroidal anti-inflammatory (NSAID), and/or disease-modifying anti-rheumatic drug (DMARDS; e.g., tumor necrosis factor inhibitors), must be stable use for at least 1 month prior to enrollment (all must be maintained throughout the study)
- English-speaking or Spanish-speaking
- negative urine toxicology screen
- negative pregnancy test
- not nursing
- use of highly effective birth control during the study for both males and females
- prior history of vaping or smoking cannabis
Exclusion
- greater than zero breath alcohol concentration
- presence of psychosis, panic disorder, or suicidal ideation or intent
- self-report of serious adverse reaction to cannabis in the past year
- smoking more than 20 tobacco cigarettes per day
- body mass index below 18.0 or above 33.0 kg/m2 range confirmed during medical exam
- all current asthma conditions (i.e., active symptomatic asthma within the last week) or current or past history of asthma triggered by smoking or vaping
- current diagnosis of dementia or Parkinson's disease
- below cut-off on mental status exam
- current diagnosis of moderate to severe traumatic brain injury
- current diagnosis of epilepsy
- individuals who are immunocompromised (i.e., post-organ transplant, those with an immune deficiency disorder such as HIV, individuals taking immunosuppressant steroids such as continuous prednisone use, and those with lupus)
- past kidney disease (e.g., glomerular nephritis, polycystic kidney disease) and/or presence of elevated creatinine
- cardiac disease confirmed via clinically significant abnormal findings on an EKG (e.g., arrhythmia, conduction abnormalities, ischemia, or evidence of past myocardial infarction), as well as diagnoses of congestive heart failure or cardiomyopathy
- abnormal vital signs
- taking any exclusionary medications
- presence of any severe cardiovascular, renal, or hepatic disorder
- below 18 or above 65 years of age
- use of cannabis in the past 1 month before commencement of study participation and throughout the study as confirmed via urine toxicology screening aa) below minimum self-reported pain level on a visual analog scale (VAS) pre-study enrollment via telephone and at baseline due to potential variability in pain level
Key Trial Info
Start Date :
May 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2023
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04269993
Start Date
May 18 2022
End Date
July 31 2023
Last Update
April 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brown University School of Public Health
Providence, Rhode Island, United States, 02903